James Xu

James Xu is a partner in Goodwin’s Technology Companies & Life Sciences group. Mr. Xu’s practice concentrates on capital markets transactions, focusing on initial public offerings, as well as securities law reporting and compliance. In his practice, Mr. Xu represents a wide variety of companies and investment banks in the technology and life sciences industries. In addition, Mr. Xu counsels clients in private financings, mergers and acquisitions, governance and other general corporate matters. He joined Goodwin in 2010.

Mr. Xu’s recent transactional experience include:

• Aerpio Pharmaceuticals’s listing as a public company through a reverse merger transaction and a concurrent $40 million private placement
• Allena Pharmaceuticals in its $75 million initial public offering
• AquaVenture Holdings in its $117 million initial public offering
• BioAmber in several follow on public offerings raising an aggregate of $120.1 million
• Borderfree in its $80 million initial public offering and subsequent $395 million sale to Pitney Bowes
• Esperion Therapeutics in several follow-on public offerings raising an aggregate of $450 million
• Mimecast in its $77.5 million initial public offering and its $66 million secondary public offering
• Neos Therapeutics in several follow-on public offerings raising an aggregate of $55 million
• ProQR Therapeutics in its $97.5 million initial public offering, several follow-on public offerings raising an aggregate of $26 million and the establishment of its at-the-market facility
• Ra Pharmaceuticals in its $91.6 million initial public offering
• scPharmaceuticals in its $90 million initial public offering
• Vascular Biogenics in its $40 million initial public offering, several follow-on public offerings raising an aggregate of $39 million and the establishment of its at-the-market facility
• Virtusa Corporation in its $91 million follow-on public offering and its $108 million private placement of preferred stock
• The underwriting syndicate in Edge Therapeutics’ $92 million initial public offering
• The underwriting syndicate in InflaRx’s $100 million initial public offering
• The underwriting syndicate in Innocoll AG’s $59 million initial public offering and its subsequent follow-on public offering raising an aggregate of $70 million
• The underwriting syndicate in Nivalis Therapeutics’ $88 million initial public offering
• The underwriting syndicate in Paylocity’s $138 million initial public offering
• The underwriting syndicate in Tokai Pharmaceuticals’ $97 million initial public offering

Prior to joining Goodwin, Mr. Xu was a Litigation Fellow at the Lawyers’ Committee for Civil Rights Under Law of the Boston Bar Association, practicing civil rights litigation in the areas of employment, housing and racial violence.

Mr. Xu co-authored “Consistency of Confusion? A Fifteen-Year Revisiting of Barton Beebe’s Empirical Analysis of Multifactor Tests for Trademark Infringement,” which was published in the Stanford Technology Law Review (2010 Stan. Tech. L. Rev. 3).